Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

I read with interest the article entitled “Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study” by Able et al. [1], which investigates the risk of erectile dysfunction and testosterone deficiency in non-diabetic, obese men prescribed semaglutide, one of the long-acting glucagon-like peptide-1 receptor agonists, for weight loss.

。

They concluded that non-diabetic men prescribed semaglutide are at increased risk of erectile dysfunction and testosterone deficiency when compared to the non-diabetic men who never received a semaglutide prescription. When the authors present possible explanation for the link between glucagon-like peptide-1 receptors and erectile dysfunction/testosterone deficiency they cited an experimental study entitled “GLP-1: A novel zinc finger protein required in somatic cells of the gonad for germ cell development “ by Li et al.

他们得出结论，与从未服用过semaglutide处方的非糖尿病男性相比，服用semaglutide的非糖尿病男性勃起功能障碍和睾丸激素缺乏的风险增加。当作者对胰高血糖素样肽-1受体与勃起功能障碍/睾丸激素缺乏之间的联系提出可能的解释时，他们引用了一项实验研究，题为“GLP-1：生殖细胞发育所需的性腺体细胞中的新型锌指蛋白”，Li等人。

[2].However, Li et al.‘s study actually investigates the role of GATA-like protein-1, a nuclear protein, in the development of gonads [2]. In that research, the authors abbreviated GATA-like protein-1 as “GLP-1”, which likely led to the confusion. I am writing to clarify the key differences between GATA-like protein-1 and glucagon-like peptide-1, two molecules often confused due to their similar abbreviations..

[2] 。然而，李等人的研究实际上研究了GATA样蛋白-1（一种核蛋白）在性腺发育中的作用。在该研究中，作者将GATA样蛋白-1缩写为“GLP-1”，这可能导致混淆。我写这篇文章是为了澄清GATA样蛋白-1和胰高血糖素样肽-1之间的关键区别，这两种分子由于其相似的缩写而经常混淆。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Subscribe to this journalReceive 8 print issues and online access251,40 € per yearonly 31,43 € per issueLearn moreBuy this articlePurchase on Springer LinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout

订阅本期刊每年可收到8期印刷版和在线访问251,40欧元每期仅31,43欧元了解更多在Springer Links上购买本文即时访问全文PDFBuy NOW价格可能需要缴纳结帐时计算的当地税费

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesAble C, Liao B, Saffati G, Maremanda A, Applewhite J, Nasrallah AA, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. Int J Impot Res. Published online May, 2024. https://doi.org/10.1038/s41443-024-00895-6Li S, Lu MM, Zhou D, Hammes SR, Morrisey EE.

参考文献C，Liao B，Saffati G，Maremanda A，Applewhite J，Nasrallah AA等。在非糖尿病肥胖患者中使用semaglutide减肥与勃起功能障碍风险增加有关：TriNetX数据库研究。Int J Impot Res.于2024年5月在线发布。https://doi.org/10.1038/s41443-024-00895-6LiS，Lu MM，Zhou D，Hammes SR，Morrisey EE。

GLP-1: a novel zinc finger protein required in somatic cells of the gonad for germ cell development. Dev Biol. 2007;301:106–16. https://doi.org/10.1016/j.ydbio.2006.07.048Article .

GLP-1：生殖细胞发育所需的性腺体细胞中的新型锌指蛋白。开发生物学。2007年；301:106-16。https://doi.org/10.1016/j.ydbio.2006.07.048Article。

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–E988. https://doi.org/10.1152/ajpendo.1997.273.5.E981Article

Nauck MA，Niedereichholz U，Ettler R，Holst JJ，Orskov C，Ritzel R等。胰高血糖素样肽1对健康人胃排空的抑制作用超过了其促胰岛素作用。Am J生理学。1997年；273:E981–E988。https://doi.org/10.1152/ajpendo.1997.273.5.E981Article

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsDepartment of Urology, Urgup State Hospital, Nevsehir, TurkeySelman UnalAuthorsSelman UnalView author publicationsYou can also search for this author in

下载参考文献作者信息作者和所属机构土耳其内夫塞希尔乌尔古普州立医院泌尿外科，土耳其塞尔曼·乌纳劳索斯尔曼·乌纳尔维尤（UnalAuthorsSelman UnalView）作者出版物您也可以在

PubMed Google ScholarContributionsConception and design, acquisition of data and drafting the manuscript, and final approval of the completed manuscript: SU.Corresponding authorCorrespondence to

PubMed谷歌学术贡献概念和设计，数据获取和手稿起草，以及完成手稿的最终批准：SU。通讯作者回复

Selman Unal.Ethics declarations

塞尔曼·乌纳尔。道德宣言

Competing interests

相互竞争的利益

The author declares no competing interests.

作者声明没有利益冲突。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Rights and permissionsReprints and permissionsAbout this articleCite this articleUnal, S. Comment on: Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study..

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。权利和许可打印和许可关于本文引用本文Nal，S.评论：在非糖尿病，肥胖患者中处方semaglutide减肥与勃起功能障碍风险增加有关：TriNetX数据库研究。。

Int J Impot Res (2024). https://doi.org/10.1038/s41443-024-00960-0Download citationReceived: 01 July 2024Revised: 15 July 2024Accepted: 30 July 2024Published: 09 August 2024DOI: https://doi.org/10.1038/s41443-024-00960-0Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Int J Impot Res（2024年）。https://doi.org/10.1038/s41443-024-00960-0Download引文收到日期：2024年7月1日修订日期：2024年7月15日接受日期：2024年7月30日发布日期：2024年8月9日OI：https://doi.org/10.1038/s41443-024-00960-0Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供